Lacosamide (Vimpat) received its initial approval from the U.S. Food and Drug Administration (FDA) on October 28, 2008.

It is an anticonvulsant medication used to treat partial-onset seizures (seizures that involve only one part of the brain) in adults and children 1 month of age and older. It is also combined with other medications to control primary generalized tonic-clonic seizures (formerly known as a grand mal seizure, a seizure that involves the entire body) in adults and children 4 years and older.

The drug is given via intravenous (IV) injection, offering flexibility in dosing and administration. The recommended dosage and administration of lacosamide depend on the patient's age, weight, medical condition, and response to other medications. Patients must follow their healthcare provider's instructions carefully and attend regular check-ups to monitor the drug's effectiveness.

Lacosamide, an antiepileptic medication, can entail common side effects like dizziness, headache, nausea, and vomiting. It might also cause blurred vision, tremors, or coordination issues. Potentially serious effects include allergic reactions, suicidal thoughts, mood changes, cardiac effects, and hypersensitivity reactions. Visual changes, Stevens-Johnson syndrome, and multi-organ hypersensitivity syndrome are rare but severe possibilities. Patients should be monitored for worsening seizures upon abrupt discontinuation. 

Lacosamide carries important warnings, including an increased risk of suicidal thoughts or behavior, necessitating vigilant monitoring for mood changes. Its potential to affect cardiac conduction requires caution in patients with heart conditions. Central nervous system-related effects such as dizziness and coordination difficulties may impact activities requiring alertness. Abrupt discontinuation can lead to increased seizure frequency. Hypersensitivity reactions, including severe skin conditions, are possible. 

Patients should be cautious about photosensitivity, and potential interactions with other medications or alcohol should be discussed with healthcare providers. Pregnant and breastfeeding individuals should seek medical advice before use, and patients with impaired kidney or liver function should have dosages adjusted. Regular communication with healthcare professionals is essential to navigate these warnings effectively.

Individuals with a history of allergic reactions to the Lacosamide or its components should avoid its use. Caution is advised for patients with preexisting heart conditions or those taking medications affecting heart rhythm due to potential cardiac effects. Pregnant and breastfeeding individuals should consult healthcare providers due to uncertain safety. Kidney function should be assessed before treatment.

1. UCB Pharma Limited, Electronic medicines compendium (EMC), [Revised on Dec 2021] [ Accessed on 5th August 2023], https://www.medicines.org.uk/emc/files/pil.2286.pdf
2. UCB, Inc, US Food and Drug Administration, [Revised on Oct 2008] [Accessed on 5th August 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf
3. Sheridan M Hoy; Lacosamide: A Review in Focal-Onset Seizures in Patients with Epilepsy; CNS Drugs; Published on May 2018; [Accessed on 5/08/2023]; https://pubmed.ncbi.nlm.nih.gov/29785508/

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.